Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01295788 |
Recruitment Status : Unknown
Verified July 2017 by Margaret Lawson, Children's Hospital of Eastern Ontario.
Recruitment status was: Active, not recruiting
First Posted : February 15, 2011
Last Update Posted : July 13, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes | Device: Simultaneous RT-CGM and Pump Initiation Device: Delayed Initiation of RT-CGM | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 144 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Simultaneous or Delayed initiation of continuous glucose monitoring |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Simultaneous vs Delayed Initiation of REAL-Time Continuous Glucose Monitoring in Children and Adolescents With Type 1 Diabetes Starting Insulin Pump Therapy |
Actual Study Start Date : | June 2011 |
Actual Primary Completion Date : | June 2014 |
Estimated Study Completion Date : | December 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Simultaneous RT-CGM and Pump Initiation
The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
|
Device: Simultaneous RT-CGM and Pump Initiation
Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
Other Name: Sensor-Augmented Pump Therapy at Pump Initiation |
Active Comparator: Delayed RT-CGM Initiation
The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
|
Device: Delayed Initiation of RT-CGM
Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy. |
- Adherence to CGM (hours per week) [ Time Frame: one year ]Number of hours of RT-CGM use per week
- A1C [ Time Frame: one year ]Hemoglobin A1C
- Readiness for change [ Time Frame: six months ]SOCRATES - Diabetes Version
- Treatment Satisfaction and Quality of Life [ Time Frame: one year ]Insulin Delivery Systems Rating Questionnaire (IDSRQ)
- Fear of Hypoglycemia [ Time Frame: one year ]Hypoglycemia Fear Scale (HFS-98)
- Barriers to Adherence [ Time Frame: one year ]Modified Barriers to Adherence Questionnaire (MBAQ)
- Perception of Barriers/Facilitators to RT-CGM Use [ Time Frame: one year ]CGM Satisfaction Scale (CGM-SAT)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Males and females age 5-18 years old.
- Established T1D diagnosis for a minimum of one year.
- Naïve to CSII therapy and ready to start CSII with the Veo pump (Medtronic) .
- Willing to use RT-CGM and to be randomly assigned to either simultaneous or delayed RT-CGM initiation.
- Regular diabetes follow up at one of the 5 participating sites.
- Internet access at home (to upload RT-CGM data).
- Parent(s) or legally acceptable representative able to speak and read English or French.
- Ability of the subject and parent(s) or legally acceptable representative to participate in all aspects of this clinical trial.
- Written informed consent must be obtained and documented, with assent of the child if <14 years of age.
Exclusion Criteria
- Conditions which in the opinion of the investigator may interfere with the subject's ability to participate in the study.
- Has received oral and/or intravenous steroid therapy (for any indication, at any dose and/or for any duration) on more than 2 separate occasions in the past 12 months. Use of inhaled and/or topical steroid therapy in the last 12 months does not exclude the subject.
- Prior use of RT-CGM for more than 50% of the time over the past 6 months.
- Prior enrollment in the current study.
- Current enrollment in another intervention trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01295788
Canada, Ontario | |
McMaster Children's Hospital | |
Hamilton, Ontario, Canada, L8S 4J9 | |
Children's Hospital of Western Ontario | |
London, Ontario, Canada, N5Y 3T2 | |
Markham-Stouffville Hospital | |
Markham, Ontario, Canada, L3P 7P3 | |
Children's Hospital of Eastern Ontario | |
Ottawa, Ontario, Canada, K1H 8L1 | |
Hospital for Sick Children | |
Toronto, Ontario, Canada, M5G 1X8 |
Study Director: | Margaret L Lawson, MD | Children's Hospital of Eastern Ontario |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Margaret Lawson, Professor of Pediatrics, Children's Hospital of Eastern Ontario |
ClinicalTrials.gov Identifier: | NCT01295788 |
Other Study ID Numbers: |
CHEO 09/05E |
First Posted: | February 15, 2011 Key Record Dates |
Last Update Posted: | July 13, 2017 |
Last Verified: | July 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |